KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $17.5 million.

  • Xenon Pharmaceuticals' Accumulated Expenses rose 9575.04% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 9575.04%. This contributed to the annual value of $12.1 million for FY2024, which is 3668.4% up from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Accumulated Expenses is $17.5 million, which was up 9575.04% from $15.2 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Accumulated Expenses' 5-year high stood at $17.5 million during Q3 2025, with a 5-year trough of $1.3 million in Q1 2021.
  • For the 5-year period, Xenon Pharmaceuticals' Accumulated Expenses averaged around $6.6 million, with its median value being $5.8 million (2022).
  • In the last 5 years, Xenon Pharmaceuticals' Accumulated Expenses crashed by 196.97% in 2022 and then soared by 16556.69% in 2025.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Accumulated Expenses stood at $5.9 million in 2021, then fell by 1.97% to $5.8 million in 2022, then surged by 51.54% to $8.8 million in 2023, then surged by 36.68% to $12.1 million in 2024, then surged by 45.13% to $17.5 million in 2025.
  • Its last three reported values are $17.5 million in Q3 2025, $15.2 million for Q2 2025, and $10.1 million during Q1 2025.